GeneSort

Company Overview

Snapshot

Founded in September 2013 by Dr. Ayala Stadler-Lagziel, GeneSort operated with 1–10 employees. The company raised $2.2 million across one funding round from Singulariteam. A significant milestone for the company was its acquisition by Hong Kong investment fund AID Partners in May 2017 for $23 million.

Business overview

GeneSort was a molecular diagnostics company focused on integrating molecular genomics with personalized therapeutic approaches. The company's core technology leveraged patients' genetic DNA profiles to assist physicians in selecting tailored treatments. GeneSort provided diagnostic services primarily in the areas of cancer and hereditary diseases, serving the Health Tech & Life Sciences sector.

Strategic signal

In July 2018, ACT, a Korean developer of cosmetic ingredients, agreed to acquire a 49 percent stake in GeneSort International for $17.7 million. This strategic move allowed ACT to enter the cancer diagnosis and treatment markets in Korea, China, and Southeast Asia, leveraging GeneSort's expertise in liquid biopsy for early cancer detection. This acquisition highlighted the continued market interest in GeneSort's diagnostic capabilities even after its initial acquisition, signaling the value of its technology for broader market expansion.

Company Intelligence Q&A

What is GeneSort's primary focus?

GeneSort is a molecular diagnostics company focused on integrating molecular genomics with personalized therapeutic approaches, assisting physicians in selecting safe, effective, and tailored treatments based on patients' genetic DNA profiles.

When was GeneSort acquired by AID Partners?

GeneSort was acquired by Hong Kong investment fund AID Partners in May 2017 for $23 million. This acquisition aimed to provide GeneSort with resources and support for expanding into Southeast Asia and other global markets.

Which investor participated in GeneSort's funding round?

In January 2015, GeneSort secured $2.2 million in funding from Singulariteam. This investment was a key step in the company's development, enabling it to advance its molecular diagnostics technologies.

What was the strategic rationale behind ACT's acquisition of a stake in GeneSort International?

In July 2018, ACT acquired a 49 percent stake in GeneSort International for $17.7 million to advance into the cancer diagnosis and treatment markets in Korea, China, and Southeast Asia. This move leveraged GeneSort's liquid biopsy technology for early cancer detection.

What types of diagnostic services does GeneSort provide?

GeneSort focuses on providing diagnostic services in the areas of cancer and hereditary diseases, utilizing genetic analysis of deep tissue to help oncologists adapt treatments to specific genetic mutations.